Io­vance’s Am­tagvi sees ‘healthy de­mand’ af­ter US ap­proval

Around 12 days af­ter win­ning an FDA thumbs up, Io­vance Bio­ther­a­peu­tics’ ad­vanced melanoma treat­ment Am­tagvi has signed on 20 pa­tients in what an­a­lysts de­scribe as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER